Want to see NSPR full AI Analyst Report?
NSPR Stock Chart & Stats
$0.92
-$0.01(-1.63%)
At close: 4:00 PM EDT
$0.92
-$0.01(-1.63%)
Day’s Range― - ―
52-Week Range$0.63 - $2.57
Previous CloseN/A
Volume15.57K
Average Volume (3M)81.70K
Market Cap
$35.68M
Enterprise Value$31.87
Total Cash (Recent Filing)$30.42M
Total Debt (Recent Filing)$1.97M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Nov 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding46,489,117
10 Day Avg. Volume32,006
30 Day Avg. Volume81,701
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.33Price Target Upside262.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$10.38M
Bulls Say, Bears Say
Bulls Say
International Revenue GrowthInternational growth and continued physician adoption demonstrate that CGuard has commercial traction outside the paused U.S. market. Expanding overseas demand can diversify revenue, support utilization of the product platform, and provide a foundation for broader growth as U.S. commercialization resumes.
Regulatory And Product PipelineThe company has several defined regulatory and product milestones rather than relying on a single development program. Successful approvals could broaden the addressable market, restore U.S. commercial access, and create multiple pathways for longer-term procedure and device growth.
Planned Cost ReductionThe planned workforce reduction should lower the recurring expense base and concentrate resources on regulatory and commercial priorities. If executed as described, annualized savings can extend financial runway, reduce the gap to breakeven, and improve operating leverage as revenue recovers.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the current business is not self-funding. Continued cash consumption can require external financing, constrain investment in clinical and commercial programs, and increase execution pressure before regulatory milestones generate meaningful revenue.
Severe UnprofitabilityLosses remain exceptionally large relative to the company’s modest revenue base, while gross profitability is not yet sufficient to support operating expenses. This cost structure makes earnings highly dependent on substantial revenue growth, successful launches, and effective expense reductions.
Regulatory Timing RiskThe commercial recovery plan depends on regulatory decisions and completion of remaining testing, but the prior schedule shift shows that milestones can move. Delays would postpone U.S. relaunch revenue, prolong cash burn, and weaken the company’s ability to execute its growth plans.
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $0.63 and its highest was $2.56 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $35.68M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Nov 10, 2026 which is in 50 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Aug 17, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.03.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.15.
How many shares outstanding does InspireMD have?
InspireMD has 46,489,117 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -10.489%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.33 (262.32% Upside)
$3.33 (262.32% Upside)
Blogger Sentiment
Neutral
NSPR Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
InspireMD
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
NSPR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of encouraging operational and regulatory progress (21% international revenue growth, constructive FDA interactions, multiple potential approvals, enrollment in a pivotal SwitchGuard study, and planned annualized cost savings of ~$9 million) alongside significant near‑term challenges (voluntary recall driving $734k in customer credits and a $612k inventory impairment, a swing to negative GAAP gross margin, a wider net loss of $14.3M, and a substantial cash decline from $54.2M to $30.4M). Management articulated a clear remediation and relaunch plan and emphasized underlying demand, but financial impacts and regulatory timing risk keep the outlook balanced between opportunity and near‑term execution/liquidity challenges.View all NSPR earnings summariesNSPR Stock 12 Month Forecast
Average Price Target
$3.33
▲(262.32% Upside)
Technical Analysis
Ownership Overview
20.47% Insiders
0.04% Mutual Funds
32.79% Other Institutional Investors
46.46% Public Companies and
Individual Investors